


What is Claimed:

1. A compound of the Formula (I):



(I)

5 wherein

the configuration at the stereogenic center (*) may be R, S, or RS (the racemate);


R₁ is selected from C₁ – C₆ alkoxy, and

10 R₂ is selected from H, or C₁– C₆ alkyl, or pharmaceutically acceptable salts or hydrates thereof.

2. A compound of Claim 1 which is 2,2-dimethyl-propionic acid 4-[2-dimethylamino-1-(hydroxy-cyclohexyl)-ethyl]-phenoxy-methylester, or a pharmaceutically acceptable salt or hydrate thereof.

15

3. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of Formula I



(I)


wherein

the configuration at the stereogenic center (*) may be R, S, or RS (the racemate);

R₁ is selected from C₁ – C₆ alkoxy, and

R₂ is selected from H, or C₁– C₆ alkyl, or pharmaceutically acceptable salts or hydrates thereof; and a pharmaceutically acceptable carrier or excipient.

4. A method of treating disorders of the central nervous system in a mammal, the method comprising providing to a mammal in need thereof a pharmaceutically effective amount of a compound of Formula I



(I)

10

wherein

the configuration at the stereogenic center (*) may be R, S, or RS (the racemate);

R₁ is selected from C₁ – C₆ alkoxy, and

R₂ is selected from H, or C₁– C₆ alkyl, or pharmaceutically acceptable salts or hydrates thereof.

15

5. The method of Claim 4 wherein the central nervous system disorder is depression.

20

6. The method of Claim 4 wherein the central nervous system disorder is generalized anxiety disorder.

7. The method of Claim 4 wherein the central nervous system disorder is panic disorder.

25

8. The method of Claim 4 wherein the central nervous system disorder is post traumatic stress disorder.

5 9. The method of Claim 4 wherein the central nervous system disorder is attention deficit disorder, with and without hyperactivity.

10 10. The method of Claim 4 wherein the central nervous system disorder is a neurodegenerative disorder.

11. The method of Claim 10 wherein the neurodegenerative disorder is selected from the group consisting of senile dementia, Parkinson's Disease, epilepsy, Alzheimer's disease, amnesia, amnesic syndrome, or Shy-Drager Syndrome.

15 12. The method of Claim 4 wherein the central nervous system disorder is anxiety.

13. The method of Claim 4 wherein the central nervous system disorder is schizophrenia or borderline personality disorder.

20

14. The method of Claim 4 wherein the central nervous system disorder is cocaine and alcohol addiction.


25 15. The method of Claim 4 wherein the central nervous system disorder is late luteal phase dysphoric disorder (also known as pre-menstrual syndrome).

16. The method of Claim 4 wherein the central nervous system disorder is autism

30 17. The method of Claim 4 wherein the central nervous system disorder is bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, and chronic fatigue syndrome.

18. The method of Claim 4 wherein the central nervous system disorder is urinary incontinence or chronic obstructive pulmonary disease.


19. The method of Claim 4 wherein the central nervous system disorder is pain.
20. The method of Claim 4 wherein the central nervous system disorder is postherpetic neuralgia.
21. The method of Claim 4 wherein the central nervous system disorder is sexual dysfunction.
- 10 22. A method of enhancing cognition in a mammal, the method comprising providing to a mammal in need thereof a pharmaceutically effective amount of a compound of Formula I



(I)


wherein:


- 15 the configuration at the stereogenic center (*) may be R, S, or RS;
 R₁ is selected from C₁ – C₆ alkyl, C₁ – C₆ alkoxy, C₃-C₆ cycloalkyl, or the moiety:



(a);

R₂ is selected from H, or C₁– C₆ alkyl; or,

R₁ and R₂ may be concatenated such that , form a

moiety having formula (b):  (b);

R₃ is selected from H or C₁ – C₆ alkyl; and

- 5 R₄ and R₅ are independently selected from H, C₁ – C₆ alkyl, C₃-C₆ cycloalkyl, C₁ – C₆ alkoxy, C₁ – C₆ thioalkoxy, -CN, -OH, -CF₃, -OCF₃, halogen, -NH₂, -NO₂, or mono or dialkylamino wherein each alkyl group has 1 to 6 carbon atoms, or a pharmaceutically acceptable salt or hydrate thereof.